

代表著作:

1. Kao YC, Lin PC, Yen SL, Huang SC, Tsai JW, Li CF, Tai HC, Lan J, Chunag IC, Yu SC, **Huang HY***. Clinicopathological and genetic heterogeneity of the head and neck solitary fibrous tumours: a comparative histological, immunohistochemical, and molecular study of 36 cases. **Histopathology**. 2016 Mar;68(4):492-501. (SCI, 2014 IF: 3.453, rank: 15/75 =20.0 % in Pathology, corresponding author*)
2. Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, Yen SL, Jung SM, Liao KC, Fang FM, **Huang HY***. NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors: a correlative study of 88 cases. **Mod Pathol** 2015 Oct;28(10):1324-35. (SCI, 2014 IF: 6.187, rank: 5/75 =6.7 % in Pathology, corresponding author*)
3. Li CF, Chen LT, Lan L, Chou FF, Lin CY, Chen YY, Chen TJ, Li SH, Yu SC, Fang FM, Tai HC, **Huang HY***. AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis. **Oncotarget** 2014 Nov 30;5(22):11588-603. (SCI, 2014 IF: 6.359, rank: 21/211 =9.9 % in Oncology, corresponding author*, 第 12 回日本臨床腫瘍學會最佳論文獎勵賞).
4. Li CF[#], Fang FM[#], Kung HJ, Chen LT, Wang JW, Tsai JW, Yu SC, Wang YW, Li SH, **Huang HY***. Downregulated MTAP Expression in Myxofibrosarcoma: A Characterization of Inactivating Mechanisms, Tumor Suppressive Function, and Therapeutic Relevance. **Oncotarget** 2014 Nov 30;5(22):11428-41. (SCI, 2014 IF: 6.359, rank: 21/211 =9.9% in Oncology, corresponding author*).
5. Li CF, Fang FM, J Lan, Wang JW, Kung HJ, Chen LT, TJ Chen, Li SH, Wang YW, HC Tai, Yu SC, **HY Huang***. AMACR amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance. **Clin Cancer Res** 2014 Dec;20(23):6141-52. (SCI, 2014 IF: 8.722, rank, 12/211=5.7 % in Oncology, corresponding author*)
6. Kao YC, Lan J, Tai HC, Li CF, Liu KW, Tsai JW, Fang FM, Yu SC, **Huang HY***. Angiomatoid Fibrous Histiocytoma: clinicopathological and molecular characterization with emphasis on variant histomorphology. **J Clin Pathol** 2014 Mar;67(3):210-5. (SCI, 2014 IF: 2.915 , rank: 19/75 =25.3% in Pathology).
7. Wei YC, Lan J, Li CF, Chou FF, Li WM, Chen YY, Li SH, Fang FM, Hu TH, Yu SC, Eng HL, Uen YH, Tian YF, Wang JC, **Huang HY***. HuR Cytoplasmic Expression is Associated with Increased Cyclin A Expression and Inferior Disease-Free Survival in Gastrointestinal Stromal Tumors

- (GISTs). **Histopathology** 2013 Oct;63(4):445-54 (SCI, 2014 IF: 3.453, rank: 15/75 =20.0 % in Pathology, corresponding author).
8. **Huang HY**, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH, Chen LT, Li CF. **ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.** **Clinical Cancer Research** 2013 Jun 1;19(11):2861-2872. (SCI 2014 IF: 8.722, rank, 12/211=5.9 % in Oncology)
 9. Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, Yu SC, Lan J, **Huang HY***. Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. **Ann Surg Oncol** 2012;19(8):2716–2725 (SCI 2014 IF: 3.930, rank: 15/198 =7.6 % in Surgery, corresponding author).
 10. Li CF[#], Fang FM[#], Wang JM[#], Tzeng CC, Tai HC, Wei YC, Li SH, Lee YT, Wang YH, Yu SC, Shiue YL, Chu PYW, Wang WL, Chen LT, **Huang HY***. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. **Ann Surg Oncol** 2012 Feb;19(2):443-54. (SCI, 2014 IF: 3.930, rank: 15/198 =7.6 % in Surgery, corresponding author)
 11. CF Hwang[#], **HY Huang[#]**, CH Chen, CY Chien, YC Hsu, CF Li, FM Fang. Enhancer of Zeste Homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth. **Int J Radiat Oncol** 2012 Feb 1;82(2):597-604. ([#], equal contribution, SCI, 2014 IF: 4.258, rank: 12/125 =9.6% in Radiology, Nuclear Medicine, and Medical Imaging)
 12. **Huang HY***, LI CF, Fang FM, Tsai JW, LI SH, Lee YT, Wei HM. Prognostic Implication of Ezrin overexpression in Myxofibrosarcomas. **Ann Surg Oncol** 2010;17(12):3212-3219. (SCI, 2014 IF: 3.930, rank: 15/198 =7.6 % in Surgery, first and corresponding author).
 13. Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, **Huang HY***. Prognostic Implication of MET Overexpression in Myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. **Mod Pathol** 2010;23(10):1379-1392. (SCI, 2014 IF: 6.187, rank: 5/75 =6.7 % in Pathology, CMRPG870751-2, corresponding author, 100 年台灣病理學會-葉曙基金會最佳論文)
 14. **Huang HY**, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH, Chen LT, Li CF. **ASS1 as a Novel Tumor**

Suppressor Gene in Myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. *Clinical Cancer Research* 2013 Jun 1;19(11):2861-2872. (SCI 2016 IF: 9.619, rank, 12/217=5.6 % in Oncology)

15. Li CF, Fang FM, J Lan, Wang JW, Kung HJ, Chen LT, TJ Chen, Li SH, Wang YW, HC Tai, Yu SC, **HY Huang***. ***AMACR* amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance. *Clin Cancer Res* 2014 Dec;20(23):6141-52. (SCI, 2016 IF: 9.619, rank, 12/217=5.5 % in Oncology, corresponding author^{*})**
16. Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, Yen SL, Jung SM, Liao KC, Fang FM, **Huang HY***. ***NAB2-STAT6* fusion types account for clinicopathological variations in solitary fibrous tumors: a correlative study of 88 cases. *Mod Pathol* 2015 Oct;28(10):1324-35. (SCI, 2016 IF: 5.728, rank: 4/79 =5.1 % in Pathology, corresponding author^{*})**
17. Li CF, Fang FM, Chen YY, Liu TT, Chan TC, Yu SC, Chen LT, **Huang HY*** Overexpressed fatty acid synthase in gastrointestinal stromal tumors: Targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib. ***Clin Cancer Res* 2017;23(16):4908-4918. (SCI, 2016 IF: 9.619, rank, 12/217=5.5 % in Oncology, corresponding author^{*}).**
18. Tsai JW, ChangChen W[#], Lee JC[#], Kao YC^{4,11,#}, Li WS, Liang CW, Liao IC, Yi-Ming Chang YM, Wang RZ, Tsao CF, Yu SC, **Huang HY*** The expanding morphological and genetic spectra of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and nonmutated cases. ***Histopathology* (SCI in press, 2016 IF: 3.523, rank: 15/79 =19.0 % in Pathology, corresponding author)**